The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | The role of stem cell transplantation in systemic light chain amyloidosis
In this video, Harsh Parmar, MD, Hackensack University Medical Center, Hackensack, NJ, comments on the role of stem cell transplantation (SCT) in systemic light chain (AL) amyloidosis, highlighting that this remains an ongoing debate in the field. With the emergence of CAR T-cell therapy, which has shown promising results in treating multiple myeloma, the role of SCT in AL amyloidosis may evolve. However, until compelling data is available from clinical trials, Dr Parmar believes that eligible patients should receive a transplant. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think there’s a lot of debate going on when it comes to the role of stem cell transplant in systemic AL amyloidosis. With all the new advances that we’re seeing in myeloma, a lot of these treatments have a role in systemic AL amyloidosis as well, particularly when it comes to the use of T-cell engagers and CAR-T therapy. We are just seeing some data that is being presented at ASCO for the utility of CAR-T therapy in myeloma where a trial found that all patients who received CAR-T had a response, an impressive response...
So I think there’s a lot of debate going on when it comes to the role of stem cell transplant in systemic AL amyloidosis. With all the new advances that we’re seeing in myeloma, a lot of these treatments have a role in systemic AL amyloidosis as well, particularly when it comes to the use of T-cell engagers and CAR-T therapy. We are just seeing some data that is being presented at ASCO for the utility of CAR-T therapy in myeloma where a trial found that all patients who received CAR-T had a response, an impressive response. So the question about stem cell transplant is once again being considered. I personally feel that if a patient is eligible for a stem cell transplant for light-chain amyloidosis, they should receive it. I know the ANDROMEDA data is also quite impressive and a lot of centers are moving away from doing stem cell transplants, particularly the ones who’ve achieved a deep state of remission. But I think this question is also being answered in the context of a clinical trial, so we have to wait and see what that trial shows eventually.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
